My Blue Dots

CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced positive symptom data from its Phase 2 ACeD-it trial evaluating its lead candidate, KAN-101, in individuals with celiac disease. The study data serves as the first symptomatic clinical proof of concept for KAN-101 and its potential as a disease-modifying treatment for celiac disease. KAN-101 ind

SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipol

DENVER–(BUSINESS WIRE)–TriSalus announces leadership changes.

BRANFORD, Conn.–(BUSINESS WIRE)–Quantum-Si’s New Preprint Showcases Protein Barcoding as a Powerful Tool for Transforming Proteomics

SAN DIEGO & OXFORD, England–(BUSINESS WIRE)– #AploScope–ONI (Oxford Nanoimaging), a life science tools company focused on developing super-resolution microscopy, announced today the launch of the Aplo Scope, a single molecule super-resolution microscope that enables scientists to observe and measure molecular interactions within cells and tissues with unparalleled precision. The Aplo Scope addresses a critical challenge in single-molecule research—capturing the intricate details of biological systems in

BELOIT, Wis. & LAGUNA HILLS, Calif.–(BUSINESS WIRE)–NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for Development and Production of Radiopharmaceutical Products

BOSTON–(BUSINESS WIRE)–MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced the promotion of Rami Rahal, Ph.D., to Partner. “We are proud to announce Rami’s well-deserved promotion in recognition of the tremendous value he has brought to the public investing team at MPM BioImpact,” said Christiana Bardon, M.D., Managing Partner of MPM BioImpact. “Our goal is to invest in companies

PEKÍN, ALAMEDA (California) y TAIPÉI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy una alianza estratégica para evaluar de forma conjunta un programa de conjugados de anticuerpos-fármacos biespecíficos de carga doble (BsAD2C). Esta colaboración combina la plataforma RenLite® de Biocytogen con la tecnología de conjugación anticuerpo-fármaco doble (AD2C) de Acepodia para enfrentar algunos de los desafíos oncológicos más difíciles, como la heterogeneidad y la resis

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &